Lead Product(s) : Suvecaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial for TGCT Treatment
Details : JZP385 (suvecaltamide) is an investigational, highly selective and state-dependent modulator of T-type calcium channels, being evaluated in adult patients with moderate to severe essential tremor.
Product Name : JZP385
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Suvecaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD/PD 2022
Details : Results showed that participants with PD who were treated with prasinezumab for two years showed slower decline of Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part 3 scores relative to participants treated with prasinezumab for o...
Product Name : PRX002
Product Type : Antibody
Upfront Cash : Inapplicable
March 16, 2022
Prothena Announces Achievement of $60 Million Milestone From Roche
Details : Company has earned a $60 million milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease.
Product Name : PRX002
Product Type : Antibody
Upfront Cash : Undisclosed
October 05, 2021
Details : The study will be designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA to include patients with early Parkinson’s disease on stable levodopa therapy.
Product Name : PRX002
Product Type : Antibody
Upfront Cash : Inapplicable
October 20, 2020
Details : The study did not achieve the primary goal, but did show signs of efficacy. Roche has begun further clinical development preparation and is reviewing the results from PASADENA Study Part 1.
Product Name : PRX002
Product Type : Antibody
Upfront Cash : Inapplicable
April 22, 2020
Details : PASADENA is a two-part Phase 2 clinical study in patients with early Parkinson’s disease that is being conducted by Roche.
Product Name : PRX002
Product Type : Antibody
Upfront Cash : Inapplicable
March 31, 2020
Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results
Details : Company will present Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. Results from Part 1 of the Phase 2 PASADENA study of prasinezumab were selected as an oral Top Abstract presentation at the upcoming Virtual 2020 MD...
Product Name : PRX002
Product Type : Antibody
Upfront Cash : Inapplicable
March 09, 2020